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Introduction
The classical Endocannabinoid System (ECS) is formed by the endocannabinoid (eCB) signaling 
substances, Anandamide (AEA) and 2-Arachidonoyl Glycerol (2-AG) as well as their G-protein 
coupled cannabinoid receptors, CB1 and CB2. Lately, new receptors sensitive to Cannabinoids (CB) 
have been discovered, encompassing the orphan GPR18 and GPR55 receptors that are modulated by 
CB-like compounds and interrelate with ECS [1].
eCBs are signaling molecules of lipid nature implicated in processes such as appetite, memory, 
reward, mood, and neuroprotection. One study revealed that activities that are not running could 
raise eCB's plasma levels related to mood or appetite alterations. Augmentation of eCB's may be 
associated with the pleasurable and rewarding effects of exercise, singing and finally some of the 
long-range beneficial effects on memory, cognition and mental health [2]. Furthermore, the ECS 
has well-settled roles in neurogenesis, neuroinflammation and synaptic plasticity [3]. Relevant to it, 
several constituents of the ECS are located along the Central Nervous System (CNS) and participate 
in homeostatic functions of great importance such as cardiovascular regulation [4] (Figure 1).
The cardiovascular effects of cannabinoids are intricate, implicating the CNS, cardiac muscles, 
vasculature, and immune cells, the latter particularly in pathophysiological conditions. The 
Rostral Ventrolateral Medulla (RVLM), nucleus tractus solitaries, and periaqueductal gray are 
examples of CNS sites where CB1 receptors, the primary mediators of this type of response, are 
concentrated [5]. For example, stimulation of the CB1 receptor in the RVLM causes the growth of 
Renal Sympathetic Nerve Activity (RSNA) and Blood Pressure (BP) in rats [6]. Moreover, systemic 
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Abstract
The endocannabinoid system is closely related to the central nervous system and exerts a promising 
therapeutic potential on it and other systems such as the cardiovascular, mainly through its 
neuromodulatory, neuroprotective and neuroinflammatory effects. For this reason, when designing 
new treatments for different relevant pathologies such as hypertension, it is necessary to take into 
account the side effects that such therapies can cause at the neurological level. Deeping knowledge of 
each cannabinoid and the molecular mechanisms that can lead to undesired results is necessary. The 
present review analyzes the psychoactive consequences of anandamide and other similar substances 
such as other endocannabinoids, phytocannabinoids and synthetic cannabinoids, to assess their 
little-explored therapeutic potential in clinical investigations. Finally, the major behavioral tests 
most used until the moment to predict possible changes in the conduct of animals treated with 
various substances of cannabinoid nature are summarized.
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administration of N-arachidonoyl glycine, a GPR18 agonist, lowers 
BP by the activation of GPR18 receptor localized in RVLM [7]. One of 
the most important cardiovascular effects of eCBs is the vasodilator, 
which, at the central nervous level, could be mediated by inhibiting 
the release of norepinephrine from perivascular sympathetic nerves 
through CB1 receptors [8,9]. The inhibition of the Fatty Acid Amide 
Hydrolase (FAAH), the primary enzyme liable for eCBs hydrolysis, 
also has cardioprotective effects on patients who suffer anxiety and 
other affective disorders where the levels of eCBs and CB1 receptors 
are altered. This nervous alteration increases the predisposition 
to suffer from various cardiovascular diseases. Thus, it has been 
described that FAAH inhibitors are capable not only of acting as 
anxiolytics and antidepressants but also have an antiarrhythmic 
response mediated by CB1 [10]. Moreover, CB2 receptors also play an 
essential role at the CNS and the cardiovascular level since they can 
modulate the neuroinflammation caused by different cardiovascular 
disorders such as ischemic brain injury in early stages, acting as 
immunosuppressant's [11].
Despite the beneficial effects of ECS regulation on the 
cardiovascular system, it is clear that this influence is also capable of 
compromising the CNS, which does not always produce the desired 
results. The most representative example of this is rimonabant, the 
first specific CB1 receptor antagonist used in the clinic for its capability 
to decrease food intake, enhance cardiometabolic parameters and 
stimulate weight loss. However, psychiatric adverse effects, related 
to an elevated risk of depression and suicidal thoughts, resulted in 
the withdrawal of this drug from the market. After this fact, clinical 
research with drugs that could affect the CNS has decreased markedly 
[12]. This conditioning supposes to waste new and necessaries 
potential therapies with cannabinoids that could be very effective 
for different types of diseases such as cardiovascular pathologies and 
others.
The present review proposes to analyze the psychoactive effects 
of Anandamide (AEA) and other related substances such as other 
endocannabinoids, phytocannabinoids and synthetic cannabinoids, 
to evaluate their weakly exploited therapeutic potential in clinical 
investigations. Additionally, the primary behavioral tests used 
to predict possible changes in the animals treated with different 
substances of cannabinoid nature are summarized.
Beneficial effects of ECS modulation on CNS
Concussive Traumatic Brain Injury (TBI) is the principal kind of 
brain injury in young adults as well as a risk factor for the appearance 
of chronic traumatic encephalopathy and other neurodegenerative 
pathologies in old age. TBI pathology usually remains refractory to 
presently available drugs [13]. Based on prior knowledge that genetic 
suppression and pharmacological FAAH blockade decrease anxiety 
and ameliorate memory, and emotional responses in humans like 
rodents, one study found that treatment with PF04457845, one novel 
FAAH inhibitor that selectively elevated the brain levels of AEA, 
improved locomotor function, memory, and learning in a mouse 
model of TB1 [14]. The accumulation of microglia, astrocytes, and 
the proinflammatory cytokines expression such as TNF-α, IL-6, and 
IL-1β in the ipsilateral TBI mouse cortex and hippocampus were 
considerably decreased by drug treatment. The enhanced locomotor 
function and working memory were partially regulated by CB1 and 
CB2 receptors activation, whereas the improvement in the spatial 
learning and memory seemed to be CB1 receptor-dependent. These 
results suggested that the FAAH selective inhibition has enormous 
potential in the therapy of TBI [13]. Moreover, using a mouse model 
of TBI, it has been discovered that the treatment of post-injury chronic 
with PF3845, another potent and selective inhibitor of FAAH, reversed 
the impairments in fine motor movement induced by TBI, working 
memory dependent on the hippocampus, and anxious type behavior. 
It decreased dentate gyrus neurodegeneration and up-regulated the 
Bcl-2 and Hsp70/72 expression in both hippocampus and cortex. 
PF3845 also blocked the elevated production of the amyloid precursor 
protein, reestablished the synaptophysin levels in the ipsilateral 
dentate gyrus, and prevented dendritic loss. Additionally, PF3845 
repressed the inducible nitric oxide synthase and cyclooxygenase-2 
expression and improved the post-TBI arginase-1 expression, 
indicating a change of macrophages/microglia from M1 to M2 anti-
inflammatory phenotype [15]. So far, clinical data confined to safety 
studies with AEA hydrolysis inhibitors have shown that in the doses 
used, they have good tolerance and do not show signs of "cannabis-
like" behaviors [16]. Furthermore, the endocannabinoid degradative 
enzymes manipulations, CB1, and CB2 receptors have shown 
promise in the modulation of cellular and molecular hallmarks 
of TBI pathology such as cell structure and remodeling, cell death, 
neuroinflammation, excitotoxicity and cerebrovascular breakdown 
[11]. Moreover, it is known that dual blockade of FAAH and TRPV1 
interferes with contextual fear memory by promoting CB1 receptor 
activation induced by AEA in the dorsal hippocampus. This fact may 
conduct to novel pharmacological treatments for Post-Traumatic 
Stress Disorder (PTSD) [17].
Also, some researchers suggest the idea that eCBs participate 
in the cognitive processes regulation such as the spatial and 
emotional memories consolidation with an important influence 
of environmental variables, for example, the light-dark cycle [18]. 
Preliminary studies in humans have also suggested that the therapies 
with cannabinoids may reduce PTSD related symptoms, including 
nightmares [19].
Recently, AEA analogs have also been well identified for its 
potential neuroprotective effects in neutralizing the degeneration of 
Alzheimer's Disease (AD) brains. It was reported that dipotassium 
N-Stearoyl Tyrosinate (NSTK), a synthetic AEA analog, could 
increase spontaneous locomotor activity, low anxiety-like behavior, 
and improve the spatial memory shortfalls in a transgenic mouse 
model with Alzheimer [20].
The most abundant and important psychoactive compound in 
Figure 1: Endocannabinoids system in the neuroprotection-
neuroinflammation cross-talk modulation.
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marijuana, Δ (9)-tetrahydrocannabinol (Δ (9)-THC), has medicinal 
properties but also provokes undesirable detrimental consequences 
on cognitive function. Of particular interest, series of studies were 
performed in squirrel monkeys in order to contrast the impact of 
different kinds of cannabinergic drugs on several assessments of 
performance including cognitive flexibility, learning, short-term 
memory, attention, and motivation. Drugs studied included Δ (9)-
THC, URB597, AEA, and its stable synthetic analog methanandamide. 
Altogether, these data suggest that AEA and its metabolically stable 
forms can have minor collateral effects on cognitive performance 
than Δ (9)-THC, probably giving a therapeutic benefit in clinical 
circumstances [21]. In this sense, the ECS manipulations could 
provoke therapeutic effects with a minor risk of unfavorable 
cannabis-like harmful effects [22]. Cannabis use has been related to 
a higher chance to develop schizophrenia as well as the worsening 
of their symptom. By the contrary, clinical studies have disclosed 
an opposite relationship between the cerebrospinal fluid AEA 
levels and symptom seriousness, indicating a therapeutic potential 
for drugs of endocannabinoid nature. Likewise, preclinical studies 
have demonstrated that these active pharmaceutical ingredients 
may reverse different behavioral problems in an animal model of 
schizophrenia. The subjacent mechanisms to the differences among 
the actions of exogenous and endogenous cannabinoids are, at 
present, undetermined [23]. Morena et al. [24] reported that aversive 
stimuli produced augmented concentrations of AEA in hippocampus, 
amygdala, and medial prefrontal cortex of rodents in a short time 
after training. Moreover, it has been suggested that this increment 
in cannabinoid levels controls emotional activation consequences on 
memory consolidation. Moreover, it was observed that the positive 
effects of exercise on spatial memory depend on the CB1 receptor 
signaling stimulation by increasing the concentrations of AEA [25]. 
Besides, other authors have reported that CB1 receptors activation 
mediated by AEA intensifies oscillatory activity and spontaneous 
bursting in the thalamus, suggesting that eCBs could have an essential 
role in control mechanisms of the sleep-wake cycle and activation 
level [26]. Also, it is important to mention that ECS regulates 
memory function in a differentiated way, depending on the stress 
level and excitation associated with the empirical context. Thus, ECS 
is an emotional regulator that cushions the stress and environmental 
context effects on cognitive processes [27].
Otherwise, methamphetamine toxicity is related to apoptosis and 
loss of dopaminergic neurons in the striatum analogous to what is 
found in various neurodegenerative pathologies. In this sense, one 
study assessed if ECS activation could decrease the neuronal toxicity 
provoked by large doses of methamphetamine on the dopamine 
system. The latest results indicated that ECS stimulation before the 
supply of an overdose of methamphetamine significantly reduced its 
neuronal toxicity by the activation of CB2 receptor and highlighted a 
protecting function for the ECS against toxic drug action and other 
external injuries to the brain [28]. Also, there is strong evidence on 
the protective role at the neuronal level of the eCB signaling cascade 
in several epilepsy models. In particular, augmented concentrations 
of eCBs prevent convulsions induced by Kainic Acid (KA). It was 
found that both AEA and its biosynthetic enzyme considerably rose 
in the hippocampus of younger rats treated with KA, while decreased 
in adult rats. The study indicated that the rise of endogenous AEA 
remarkably reversed epileptiform bursting induced by KA in rats 
[29].
To highlight, Human Immunodeficiency Virus type 1 (HIV-1) 
is considered a chronic pathology that mainly affects the brain and 
provokes HIV-1-associated neuronal and cognitive upsets. HIV-
1 does not infect neuronal cells but generates viral toxins, such as 
Transactivator of transcription (Tat), that disturb the equilibrium 
of neuronal calcium resulting in synaptodendritic lesions and cell 
death. In particular, it was evaluated the neuroprotective effects 
of AEA and 2-AG on Tat excitotoxicity in primary cell cultures of 
Prefrontal Cortex Neurons (PFC), and if CB receptors are related 
with this neuroprotection. The treatment with AEA and 2-AG 
decreased excitotoxic concentrations of intracellular calcium and 
induced neuronal viability after Tat exposure, which was avoided by 
rimonabant, a CB1 antagonist, but not by AM630, a CB2 antagonist. 
In general, these results suggest that eCBs provides protection to 
PFC neurons from in vitro Tat excitotoxicity through a mechanism 
mediated by CB1 receptor. Therefore, the ECS also might have 
hopeful targets for the therapy of neurodegenerative disorders linked 
with HIV-1 infection (Figure 2) [30,31].
Adverse effects of cannabinoids and related substances
It is necessary to consider that CB1 and CB2 receptors have both 
likenesses and dissimilarities in their pharmacological behavior. 
Both admit several types of agonist and antagonist compounds and 
generate an array of different responses. Alternative splice variants, 
natural polymorphisms, distribution, phylogeny, and signaling 
pathways can also promote their pharmacological diversity [32]. For 
this reason, many times these same receptors that participate in all 
the beneficial effects of the cannabinoids mentioned in the previous 
section can also in certain circumstances, mediate different adverse 
effects caused by them. In this section, some of these situations are 
presented.
Thus, some studies suggest that high concentrations of AEA in the 
hippocampus and neocortex as a consequence of acute administration 
of URB597 -a FAAH inhibitor-, prejudice Long-Term Potentiation 
(LTP), learning and memory by the activation of CB1 receptor. These 
discoveries also indicate that pharmacological increase of AEA above 
normal levels is also harmful to the subjacent physiological responses 
[33]. Yu et al. [34] showed that AEA could disturb neuronal cell 
function both through an activator of the CB1 receptor, and by 
serving as a precursor of the arachidonic acid, a potent agonist of 
PPARβ/δ, a nuclear receptor in turn up-regulating multiple genes 
associated with cognition. Furthermore, it was displayed that FABP5, 
a fatty acid-binding protein, both stimulates the AEA hydrolysis into 
arachidonic acid and thus decreases brain eCB levels, and directly 
transports arachidonic acid to the cell nucleus where it gives it to 
PPARβ/δ, allowing its activation. In according, FABP5 removal 
in mice causes excessive accumulation of AEA, avoids PPARβ/δ 
activation in the brain, and notably affects learning and memory 
dependent on the hippocampus. Another study investigated if FAAH 
genetic deletion also impacts on age-related neuroinflammation. The 
results suggested that life-long increase of AEA levels alters microglial 
regulation and promotes pro-inflammatory modifications [35].
On the other hand, synthetic cannabinoids are a group of novel 
compounds which all act like THC but are chemically sundry. 
Anxiety, agitation, hypertension, paranoia, and seldom renal failure 
and myocardial infarction are some undesired effects of these 
compounds [36]. A case study reported that a potent synthetic 
cannabinoid (NM2201) produced several undesirable effects at CNS 
level such as agitation, double incontinence, lack of coordination 
on the left side, aphasia, generalized hypertonia, hyperreflexia, left 
Walter Manucha, et al., Annals of Pharmacology and Pharmaceutics
4Remedy Publications LLC. 2019 | Volume 4 | Issue 2 | Article 1168
hemiparesis, dense diaphoresis, fever, tachycardia, hypertension, and 
seizures [37]. Another synthetic cannabinoid, JWH-210, is a strong 
CB1 receptor agonist and also has adverse effects at the CNS level 
such as tachycardia, nausea, drowsiness, hypokalemia, hypertension, 
restlessness and agitation, diplopia, convulsions, syncope, cerebral 
convulsions and signs of sympathomimetic toxicity [38] (Figure 2).
ECS in the neuroprotection-neuroinflammation cross-talk 
modulation
CB receptors and associated orphan GPRs are highly expressed in 
the immune system and CNS and regulate many neurophysiological 
processes, including critical events linked to neuroinflammation. 
Indeed, these receptors have been suggested as novel therapeutic 
targets for many brain alterations in which neuroinflammation is 
a crucial characteristic, for example, Alzheimer's Disease (AD) and 
Multiple Sclerosis (MS) [1]. Aberrant activation of the Toll-Like 
Receptor (TLR)'s causes sustained neuroinflammation and has been 
related to psychiatric and neurodegenerative disorders. One study 
analyzed the effect of URB597 on neuroinflammation, physiological 
and behavioral troubles after TLR3 agonist administration to female 
rats. The results demonstrated that improving FAAH substrate levels 
inhibits the microglia/macrophage activation mediated by TLR3 
and associated symptoms such as nociceptive responding, fever and 
anxiety-like behavior. These data provide evidence of FAAH could 
also be a new therapeutic target for neuroinflammatory diseases [39]. 
Moreover, mice with lack of FAAH showed reduced neuritic plaques, 
soluble amyloid levels, and gliosis. These data intensify the idea of 
a role for the ECS in neuroinflammation and open new approaches 
to the importance of regulating eCB levels in the inflamed brain. 
The same study informed that CB1 receptor blockade exacerbated 
inflammation in a transgenic mouse model of Alzheimer disease [40].
About the immunity of CNS, the activation of microglia is a 
polarized process spitted in potentially neurotoxic phenotype M1 
and neuroprotective phenotype M2, preponderant during chronic 
neuroinflammation. In this context, the ECB system represents a 
promising target to control the equilibrium between both microglial 
phenotypes, since AEA as an immune regulator in the CNS. One study 
evaluated the effect of AEA on changes induced by lipopolysaccharide 
in rat primary microglial cultures. It was shown that the ECS plays a 
critical role in the modulation of neuroinflammation by control of 
the M1 phenotype activation. This effect was mainly mediated by the 
CB2 receptor, despite functional interaction with GPR18/GPR55 may 
happen [41]. Mecha et al. [42] showed that 2-AG and AEA might be 
capable of acting by means of CB1 and CB2 receptors to stimulate 
the acquisition of an M2 phenotype in microglia cultures. It was 
presented three facts prove that the ECS is crucial for the acquirement 
of the M2 phenotype: (i) M2 polarization took place in the treatment 
with the two main endocannabinoids 2-AG, and AEA in cell cultures 
of microglia; (ii) CB receptor antagonists blocked M2 polarization; 
and (iii) M2 polarization was dampened in microglia from CB2 
receptor knockout mice.
Also, it was demonstrated that AEA protects neuronal cells from 
oxidative injury in rodent models. It is known that neuronal NADPH 
oxidase 2 (Nox2), activation promotes to oxidative harm of the brain, 
and its inhibition can reduce this damage. In this regard, the mouse 
hippocampal neuron cell line HT22 was treated with hydrogen 
peroxide (H2O2) to imitate oxidative lesion of neurons. The protecting 
effect of AEA was evaluated by determining apoptosis, cell metabolic 
activity, cellular morphology, Lactate Dehydrogenase (LDH) release, 
antioxidant and oxidant levels and Nox2 expression and intracellular 
Reactive Oxygen Species (ROS). HT22 cells treated with H2O2 showed 
morphological modifications, reduced LDH release, lower metabolic 
activity, elevated concentrations of intracellular ROS and oxidized 
Glutathione (GSSG), decreased Superoxide Dismutase (SOD) levels, 
reduced Glutathione (GSH) and augmented NOX2 expression. 
AEA impeded these effects, a response suppressed by concurred 
administration of CB1 antagonist AM251 or CB1-siRNA. These 
results showed that Nox2 inactivation participates in cytoprotection 
induced by AEA against oxidative stress through CB1 activation in 
HT22 cells [43].
Additionally, a regulatory function of CB receptors and 
their agonists on the attenuation of the N-Methyl-D-Aspartate 
receptor (NMDAr) activation has been proved. Quinolinic acid 
(QUIN), an excitotoxic endogenous analog of glutamate, selectively 
stimulates NMDAr and has been shown to intervene in various 
neurodegenerative pathologies. WIN, a synthetic agonist of CB 
receptors and AEA, produced beneficial effects on the loss of cell 
viability induced by QUIN. The QUIN provoked lipid peroxidation, 
early mitochondrial dysfunction, and Reactive Oxygen Species 
(ROS) production, which was partially or wholly avoided by WIN 
pretreatment, but not when WIN was aggregated concomitantly with 
QUIN to rat brain synaptosomes cultures. These results suggested a 
modulatory and neuroprotective role of CB in the early toxic events 
provoked by inductor agents of this type of processes [44,45].
Other neuroprotective findings associated to ECS were recently 
established, and where the pretreatment with the Cannabidiol (CBD) 
phytocannabinoid in rats with right middle cerebral artery occlusion 
produced a considerable reduction in infarction, brain edema, and 
blood-brain barrier permeability in contrast to the group that received 
the vehicle. CBD also produced a down-regulation of TNFR1, TNF-α, 
and NF-кB expression. This fact demonstrated that CBD has a 
neuroprotective effect (mainly through deletion of TNFR1, TNF-α, 
and NF-кB) on ischemic injury [46].
From these findings, neuroscience as a branch of knowledge 
has made unremitting efforts to contribute to the development of 
multiple techniques and scientifically validated methods to properly 
study the effect of this type of substances. It is of central relevance to 
be able to apply reliable methodologies in the analysis of drugs that 
simultaneously involve systemic therapeutic effects and at the CNS 
level, which are not always beneficial for the latter (Figure 1).
Figure 2: Endocannabinoids system modulation and its beneficial/harmful 
effects at central nervous system level.
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Behavior tests used in the evaluation of cannabinoid 
effect
Concerning the above, it results in great relevance to know 
the effects on the CNS that can cause different treatments with 
cannabinoids and related substances. Multiple behavioral tests can be 
used in animals to evaluate the facts mentioned. The choice of one or 
another will depend on the pathology studied and the therapeutic use 
of the cannabinoid in question. Each test provides information on 
various aspects related to the different ways in which the behavior of 
a living being can be affected during these therapies. The most used 
behavioral tests so far in the field of research with cannabinoids and 
related substances are summarized below.
The Elevated Plus Maze (EPM) is at present one of the key study 
implemented in animals for evaluating anxiety produced by different 
cannabinoids. Anxiolytic or anxiogenic drugs increment or reduce, 
respectively, open arms exploration. Thigmotaxis, a tendency to 
be near to vertical surfaces, provokes those rodents to evade open 
arms in the EPM. This test consists in that rodents are placed in the 
center of the labyrinth, and a video-tracking system for 5 min records 
entries/duration in each arm. Other ethological parameters such as 
the time of permanence at the end of the open arms, considered the 
most anxiogenic area of this test, can also be observed. High activity 
in open arm (number of entries and duration of each one) reflects 
anxiolytic behavior. Some studies where it was investigated the effect 
of marijuana, AEA, THC, CBD and synthetic cannabinoids such as 
JWH133, WIN 55, 212-2, URB-597, and AM-251, showed, in general, 
an anxiolytic effect of the activation of CB receptors and an opposite 
answer by blocking it [47-56].
The Novel Object Recognition Test (NORT) is also a behavioral 
trial very common for the study of several aspects of memory and 
learning in mice and the influence of cannabinoids in them. The NORT 
is quite simple, and its duration is usually three days: habituation day, 
training day, and testing day. During training, the rodent explores 
two equal objects. Later, on test day, one of the training objects is 
substituted with a novel object. Due to the animal have an inborn 
preference for novelty it will spend most of its time at the novel 
Behavioral Test Substance Observable Parameters Effects
Elevated Plus 
Maze
Marijuana (blend of fitocannabinoids), marijuana 
and anandamide, WIN 55, cannabidiol, WIN 55, 
URB-597, AM-251, Tetrahydrocannabinol, and 
JWH133.
Duration and 
entries in the open 
and closed arms
No affect the cognitive performance, mild anxiolytic effect, biphasic 
effect on locomotors activity with marijuana, exploration and locomotion 
decrease with anandamide
No impairment of spatial preference or memory, alterations in decision 
making
None, anxiolytic effect, ansiogenic effect without previous stress, 
anxiolytic effect with previous stress
CB receptors blocking provoke an anxiety behavior while activation 
exerts an anxiolytic action
Males and females are equally susceptible to changes in emotional 
behavior when THC exposure occurs before the puberty stage; 
however, if THC exposure happens after puberty, males are more 
sensitive to the anxiolytic effects
CB2KO (CB2 knock-out) mice are more anxious than WT (wild-type) 
counterparts
Novel Object 
Recognition Marijuana (blend of fitocannabinoids), cannabidiol
Exploration period 
of unknown object 
and locomotion
No affect the cognitive performance, antidepressant effect, memory 
improvement
Open Field
Marijuana, WIN 55, marijuana and anandamide, 
cannabidiol, cannabidiolic acid, cannabidiol and 
anandamide
Periods in the 
peripheral and the 
central zone of the 
field
Mild anxiolytic effect , none, biphasic effect on locomotors activity with 
marijuana and exploration and locomotion dicrease with anandamide, 
no changes in general exploratory activity, anxiolytic effect, 
antidepressant effect
Somatic signs of 
withdrawal Marijuana, tetrahydrocannabinol and JWH-018
Number of somatic 
signs Dependence of marijuana
Tail suspensión Cannabidiol, tetrahydrocannabinol and JWH-018 Immobility time, struggling time Antidepressant effect, dependence of marijuana
Marble burying Cannabidiol, tetrahydrocannabinol and JWH-018 Number of buried marbles Anticompulsive effects, dependence of marijuana
Social interaction JWH133, cannabidiol, tetrahydrocannabinol
Agressive behavior, 
time spent with the 
novel mouse
Reduction in the level of aggression by activation of CB2 receptor, 
memory improvement, low affection of social interaction
Prepulse inhibition Tetrahydrocannabinol Acoustic startle habituation None
Forced swim
Tetrahydrocannabinol, cannabidiol and 
anandamide oleamide, JWH 133, AM251, and 
AM 630
Time of fight
Females are lesser sensitive to the antidepressant effects of THC, 
antidepressant effect, antidepressant effect of CB receptors agonists 
and attenuation of these effects by their antagonism
Conditioned place 
preference WIN 55212-2
Time spend in an 
area associated 
with a drug
Higher propensity to develop addiction to cocaine
Forelimb grip 









Cannabidiolic acid Feeding latency None
Resident intruder JWH133 Aggressive behavior Reduction in the level of aggression by activation of CB2 receptor
Table 1: Main tests to evaluate effects observed in rodents as a consequence of the use of cannabinoids.
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object, whenever the rodent identifies the familiar object. Also, the 
NORT can also be modified according to the requirements. The 
retention interval can be abridged to evaluate short-term memory or 
lengthened to assess long-term memory. Pharmacological treatment 
can be used at various times before training, after training, or before 
recall to analyze different stages of learning (i.e. acquisition, early 
or late consolidation, or recall). In general, the NORT is a relatively 
low-stress, effective test for memory in rodents, and is suitable for 
the finding of neuropsychological modifications following biological, 
pharmacological, or genetic manipulations. Some authors informed 
using this test, that marijuana does not cause cognitive changes in 
memory. Also, it has been shown that CBD causes antidepressants 
effects and improves memory [48,53,55].
The Open Field Test (OFT) is another of the most used 
experimental test to examine general locomotor activity levels, 
anxiety, and willingness to explore in animals (usually rodents) in the 
evaluation of cannabinoid effects on CNS. Rodents show a natural 
aversion to brightly lit open areas. Reduced levels of anxiety lead to 
augmented exploratory behavior. Incremented anxiety will result in 
less locomotion and preference to stay near to the walls of the field. 
The OF is an arena with barriers to prevent escape. Generally, the 
area is marked with a grid and square crossings. Behavioral patterns 
measured in the open field test include frequency of entrance to the 
central grid, time of permanence in the center or the periphery of 
the open field, standing, frequency of defecation and urination, 
among others. Some authors have reported that marijuana in the 
OFT produces a dual effect that consists of a first stage where the 
locomotor activity is increased and a later stage where an effect of 
reduced locomotion and exploration is manifested. It has also been 
observed that cannabidiolic acid causes a decrease locomotor and 
exploratory activity in OFT, while CBD and AEA provoke their 
increase, as a consequence of an anxiolytic effect of cannabidiolic acid 
and a mild antidepressant effect of CBD and AEA [47,49,53,57-59].
Somatic signs of withdrawal produced by different cannabinoids 
were measured in one study by putting each rodent into an empty, 
plastic test chamber within a sound-attenuating chamber equipped 
with a ventilator and white LED lighting. The dependent variables 
analyzed were incidences of paw tremors (clapping of the forepaws), 
and head twitches (twisting of the head). These dependent variables 
were selected because they have been observed systematically in 
mice submitted to THC withdrawal [60]. In another study where the 
same test was used to determine the signs of somatic abstinence, it 
was evaluated aspects such as body blemishes, tremors in the cheeks, 
blinking eyes, fluttering of the front legs, panting, genital licking, 
grooming, shaking of the head, ptosis, teeth blinking, contractions 
and yawns [47]. This test was used by some researchers to monitor 
drug dependence on substances with addictive effects such as 
marijuana and THC, its majority component.
Tail suspension test has been used for evaluating the action of 
THC and CBD on the behavior of mice that were hung by their tails 
with scotch tape from a horizontal bar situated roughly 40 cm above 
a counter and video recorded for 6 min. The time the mice actively 
fight was scored using the software. The active fight was considered 
as one or more legs recurrently kicking within one second or arching 
of the spine, without head movement. CBD has demonstrated 
antidepressant effects through this test, which has also been used in 
the evaluation of withdrawal syndrome caused by THC and synthetic 
cannabinoids [54,60].
The Marble burying test also analyzed the central nervous effects 
of THC and CBD. Plastic test chambers filled with wood bedding 
were putting within a sound-attenuating chamber equipped with a 
ventilator and LED lighting. Twenty-five clear glass marbles were laid 
through the top of the leveled bedding. Each animal was put singly 
into the chamber and enabled to explore for 20 min freely. At the end 
of the test, each rodent was removed, and the number of unburied 
marbles (≥ 1/3 of the surface showing) was registered then subtracted 
from the 25 total marbles. Locomotor activity was concomitantly 
recorded for the duration of the test by a camera placed on the top 
of the test chamber. The video data were examined in real time using 
the software. Dependent variables included: the number of marbles 
buried and the total time immobile. This test evaluates somatic and 
other behaviors including grooming, digging, rearing, scratching, 
and retropulsion. This test has confirmed the absence of compulsive 
effects after the administration of CBD and the dependence on 
marijuana observed after treatment with THC [58,60].
The social interaction test assesses sociability and social 
recognition memory by quantifying the amount of time an 
experimental rodent spends nearby a novel, caged "target" mouse, in 
comparison with an empty chamber and a chamber with a cage but 
no “target” mouse. In studies performed with THC and other CB2 
agonists, each experimental animal was acclimated, first, in the empty 
middle chamber for 10 min, and then in the whole chamber for 
another 10 min. After this stage, a novel same-sex "target" rodent was 
placed in one of the cages in the lateral chamber, while the other wire 
cage was emptied. The plastic doors were unlocked for the 10 min 
test. The total time spent in each chamber and time spent immobile 
by mice were each measured using the software. In some studies, 
standard adversaries became temporarily anosmic by intranasal 
lavage with a 4% zinc sulfate solution one day before testing. This 
sort of rodent causes an attack response in its opponent but does not 
provoke the other animal or defend itself, since it is unable to perceive 
a urine pheromone of the experimental animals which functions as 
a signal for obtaining aggressive behavior in rodents with a normal 
olfactory sense [52,60]. Another variant of this trial, it is to use a 
second unknown standard adversary laid in the formerly empty 
chamber so that the test rodent had the option to explore either the 
known rodent (from the prior trial) or the new, strange rodent [48]. 
Analyzed parameters are usually social behaviors such as following 
(the pursuit of one animal by another), sniffing (mutual), climbing 
over and crawling under the partner and allogrooming, genital 
investigation (smelling the anogenital area); and non-social behaviors 
such as locomotion (horizontal exploration) and rearing (vertical 
exploration). This test has determined the reduction in the levels of 
aggression of rodents mediated by CB2 receptors, the improvement 
in memory after the use of CBD and the absence of effects that alter 
the social interaction in animals treated with THC [61].
Prepulse Inhibition (PPI) is a neurological response in which a 
fainter prestimulus (prepulse) overrides the response of an organism 
to an ensuing vigorous and alarming stimulus (pulse). The stimuli 
generally used are acoustic. If prepulse inhibition is high, the 
corresponding one-time startle response is low. A shortening of 
the amplitude of scare translates into the capability of the CNS to 
temporarily habituate to a strong sensory stimulus when a previous 
subtle signal is given to alert the organism. On the contrary, lackings 
of prepulse inhibition are evidenced in the disability to select out the 
needless information and they have been related with anomalies of the 
sensorimotor system. Such deficiencies are recognized in pathologies 
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like Alzheimer's disease and schizophrenia, and individuals under 
the effect of different drugs. For this reason, PPI has also been used 
for determining the cannabinoid influences on CNS. Some authors 
who have used this test have reported that THC has not caused any 
alteration in the habituation to acoustic stimuli [56,60].
Forced Swim Test (FST) is sufficiently sensitive to show 
augmented immobility in animals with depression. Rats are placed 
into a transparent Plexiglas cylinder loaded to 30 cm with water 
between 23°C and 25°C and coerced to swim for 5 min. The test is 
carried out in a small dark room and sessions were videotaped for 
posterior behavioral evaluation. Latency time of immobility and total 
time spent swimming/frightening and motionless are estimated as 
the dependent measures. Antidepressant drugs intensificate 
escapement behavior decreasing the immobility time values, while an 
increment in immobility is considered as a depressive-like behavior. 
The test has also been used in some studies to establish the potential 
depressive/antidepressive effect of cannabinoids. In general, the 
studies that have used this test, have led to conclude that the CB 
receptors activation by agonists such as THC, CBD, AEA, and 
synthetic cannabinoids, produces antidepressant effects that result in 
an increase in the time of fight of rodents in water [62,59,56].
Conditioned Place Preference (CPP) -a form of Pavlovian 
conditioning -is implemented to measure the motivational effects of 
different substances in rodents. The researchers can infer the 
animal's liking for the stimulus by mean of time that an animal 
spends in an area associated with a stimulus. It is possible to evaluate 
potential addictive effects using the rewarding effects of a drug as 
cannabinoids. One study carried out with the synthetic cannabinoid 
WIN 55212- 2 showed that the CB receptors activation by this 
agonist increases the predisposition to cocaine addiction, which is 
why its use is not recommended for recreational purposes [63].
The forelimb grip strength test is an extensively used method to 
appraise skeletal muscle performance in rodents. Animals are put 
with forelimbs grabbing a trapeze bar plugged into a digital force 
gauge, and then they are homogeneously pulled by the tail base away 
from a bar along the horizontal plane until grip was liberated and 
maximum force registered. One study where it was analyzed the 
effect of cannabidiolic acid on muscle strength of rodents showed 
that there is no effect associated with this substance that affects 
motor ability at the CNS level [57].
The Light/Dark Box (LDB) is a well-known animal model used 
in studies with cannabinoids to evaluate unconditioned anxiety 
responses in rodents. The apparatus consists of a closed, black acrylic 
chamber linked via a small gate to an open, white and illuminated 
acrylic chamber of the same proportions. Animals are put within the 
clear chamber in front of the entry hole and behavior is video 
registered for 5 min in order to evaluate the amount of entries within 
the light sector and their duration. Rodents typically spend the least 
time in the clear box than in the dark compartment. If rodents are 
injected with anxiolytic drugs, the percentage of time spent in the 
clear room will increase. Locomotion and standing, which is when 
the rodent stands up on its hind legs and is a sign of exploration, in 
the dark chamber also increase. When injected with anxiogenic 
drugs, animals spend more spent in the dark compartment. To 
highlight, only natural stressors such as light are used. Additionally, 
there is a variation of this method to evaluate aversive memory, and 
it consists in to apply a little electric footshock to the animal when it 
is in the dark box. This variation requires prior training and is 
known as Fear Conditioning test or also denominated Passive 
Avoidance test, which appraises hippocampal and amygdala 
dependent associative learning, therefore, a previous neutral stimulus
provokes a dread reaction after it has been paired with an aversive 
stimulus. Based on this test, it was determined that CBD and 
cannabidiolic acid do not affect aversive memory in rodents. 
However, CBD could cause a mild anxiolytic effect in animals 
subjected to a previous aversive stimulus [48,50,57].
The Novelty-suppressed feeding is also used to check the 
antidepressant effect of cannabinoids and related substances. In this 
test is to measure the latency time from the onset of feeding and the 
amount of feed consumed when animals are placed in an 
illuminated box with a weighed quantity of standard laboratory 
chow. Antidepressive drugs produce stimulation of feeding in the 
rodents tested and vice-versa. The absence of central nervous effects 
of cannabidolic acid was demonstrated once again with this test 
since it did not alter the feeding behavior in the animals studied [57].
The Resident-intruder procedures test evaluates aggressive 
behavior in rodents. Resident mice are isolated for ten days before 
the experimental procedure. Later, intruder rodents of similar 
weight and age are placed in boxes in groups of five. Each session 
consists of putting an intruder animal in the resident’s home box for 
5 min. Animals receive two training sessions on the first day and two 
test sessions on the second day. The decrease in aggressive behavior 
mediated by CB2 receptors and induced by its synthetic agonist 
JWH133 was reconfirmed by using this test, with results similar to 
those observed with the social interaction test [52].
These tests, the main parameters that each one evaluates and the 
main effects that are observed with them as a consequence of the use 
of different cannabinoids in rodents are summarized in Table 1.
Conclusion and Prospects
The increasing study of the pharmacological properties of 
endocannabinoids and the modulation of ECS has revealed an 
exciting approach to the discovery and development of new drugs 
with multiple therapeutic properties. To highlight is especially 
interesting in the search for alternative treatments more effective 
than those used so far for diseases with high rates of morbidity and 
mortality worldwide such as cardiovascular diseases, particularly 
arterial hypertension. The simultaneous affectation of the CNS in 
these therapies is a fundamental factor to consider since many of 
them can interfere with cognition such as memory, learning and 
other aspects related to neuroinflammation (Figure 1). Despite this, it 
has been observed that endocannabinoids such as anandamide have 
few adverse effects at the CNS level, unlike the phytocannabinoids, 
synthetic cannabinoids and antagonists of CB receptors. In fact, these 
molecules act on common receptors due to a similar spatial 
configuration, however, their structure is not identical between them 
(Figure 2). For this reason, the competition and displacement of 
endogenous ligands of the ECS by exogenous cannabinoids provokes 
an alteration in the CNS normal functioning, leading to the 
associated side effects [64].
In this sense, the in-depth knowledge of each cannabinoid and 
the molecular mechanisms that can lead to undesired results is 
necessary. Researchers are the primary responsibilities that the use 
of cannabinoids in the biomedical field is no longer considered a 
taboo and conversely, begins to take advantage of its enormous 
therapeutic potential.
As future perspectives, new animal models could be investigated, 
and new behavioral tests developed to obtain increasingly precise 
and representative results of the effects of cannabinoids in humans. 
Additionally, new forms of drug administration could be used, such 
as nanostructured systems, which allow drug localization and targeting
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